PMID- 35283064 OWN - NLM STAT- MEDLINE DCOM- 20220816 LR - 20220823 IS - 1878-0938 (Electronic) IS - 1878-0938 (Linking) VI - 42 DP - 2022 Sep TI - Impact of First-Phase Ejection Fraction on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation. PG - 55-61 LID - S1553-8389(22)00107-5 [pii] LID - 10.1016/j.carrev.2022.02.023 [doi] AB - BACKGROUND: First-phase left ventricular ejection fraction (LVEF1) is an early marker of left ventricular remodeling. Reduced LVEF1 has been associated with adverse prognosis in patients with aortic stenosis (AS) and preserved left ventricular ejection fraction (LVEF). It remains to be determined, whether reduced LVEF1 differentiates clinical outcomes after aortic valve replacement. OBJECTIVES: We investigated the impact of LVEF1 on clinical outcomes in patients undergoing transcatheter aortic valve implantation (TAVI) for symptomatic severe AS with preserved LVEF (>/= 50%). METHODS: In the prospective Bern TAVI registry, we retrospectively categorized patients according to LVEF1 as assessed by transthoracic echocardiography. Clinical outcomes of interest were all-cause mortality and residual heart failure symptoms (New York Heart Association (NYHA) functional class III or IV) at 1 year after TAVI. RESULTS: A total of 644 patients undergoing TAVI between January 2014 and December 2019 were included in the present analysis. Patients with low LVEF1 had a lower LVEF (62.0 +/- 6.89% vs. 64.3 +/- 7.82%, P < 0.001) and a higher left ventricular mass index (129.3 +/- 39.1 g/m(2) vs. 121.5 +/- 38.0 g/m(2); P = 0.027) compared to patients with high LVEF1. At 1 year, the incidence of all-cause/cardiovascular death, and NYHA III or IV were comparable between patients with low and high LVEF1 (8.3% vs. 9.2%; P = 0.773, 3.9% vs. 6.0%; P = 0.276, 12.9% vs. 12.2%; P = 0.892, respectively). CONCLUSIONS: Reduced LVEF1 was not associated with adverse clinical outcomes following TAVI in patients with symptomatic severe AS with preserved LVEF. CLINICAL TRIAL REGISTRATION: https://www. CLINICALTRIALS: gov. NCT01368250. CI - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Tomii, Daijiro AU - Tomii D AD - Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland. FAU - Okuno, Taishi AU - Okuno T AD - Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland. FAU - Demirel, Caglayan AU - Demirel C AD - Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland. FAU - Praz, Fabien AU - Praz F AD - Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland. FAU - Lanz, Jonas AU - Lanz J AD - Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland. FAU - Stortecky, Stefan AU - Stortecky S AD - Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland. FAU - Windecker, Stephan AU - Windecker S AD - Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland. FAU - Pilgrim, Thomas AU - Pilgrim T AD - Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland. Electronic address: thomas.pilgrim@insel.ch. LA - eng SI - ClinicalTrials.gov/NCT01368250 PT - Clinical Trial PT - Journal Article DEP - 20220226 PL - United States TA - Cardiovasc Revasc Med JT - Cardiovascular revascularization medicine : including molecular interventions JID - 101238551 SB - IM CIN - Cardiovasc Revasc Med. 2022 Sep;42:62-63. PMID: 35803880 MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - Humans MH - Prospective Studies MH - Retrospective Studies MH - Stroke Volume MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome MH - Ventricular Function, Left OTO - NOTNLM OT - Aortic stenosis OT - First-phase ejection fraction OT - Left ventricular ejection fraction OT - Left ventricular remodeling OT - Transcatheter aortic valve replacement COIS- Declaration of competing interest Dr. Windecker reports research and educational grants to the institution from Abbott, Amgen, Astra Zeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, V-Wave. Dr. Windecker serves as unpaid advisory board member and/or unpaid member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, Astra Zeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, Med Alliance, Medtronic, Novartis, Polares, Sinomed, V-Wave and Xeltis, but has not received personal payments by pharmaceutical companies or device manufacturers. He is also member of the steering/executive committee group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration. Dr. Pilgrim reports research grants to the institution from Edwards Lifesciences, Boston Scientifc and Biotronik, personal fees from Biotronik and Boston Scientific, and other from HighLife SAS and Medira. Dr. Pilgrim is a proctor for Medtronic. Dr. Stortecky reports research grants to the institution from Edwards Lifesciences and Medtronic, and personal fees from Boston Scientific, Teleflex, and BTG. Dr. Praz reports travel expenses from Abbott, Edwards Lifesciences, and Polares Medical. Dr. Okuno reports speaker fees from Abbott. All other authors have no relationships relevant to the contents of this article to disclose. EDAT- 2022/03/15 06:00 MHDA- 2022/08/17 06:00 CRDT- 2022/03/14 05:41 PHST- 2021/12/22 00:00 [received] PHST- 2022/02/23 00:00 [revised] PHST- 2022/02/23 00:00 [accepted] PHST- 2022/03/15 06:00 [pubmed] PHST- 2022/08/17 06:00 [medline] PHST- 2022/03/14 05:41 [entrez] AID - S1553-8389(22)00107-5 [pii] AID - 10.1016/j.carrev.2022.02.023 [doi] PST - ppublish SO - Cardiovasc Revasc Med. 2022 Sep;42:55-61. doi: 10.1016/j.carrev.2022.02.023. Epub 2022 Feb 26.